MindWalk expands GLP-1 program with AI-discovered longevity pathway

AUSTIN, Texas - MindWalk Holdings Corp. (NASDAQ:HYFT), a $79.85 million market cap biotech company that has seen its stock surge over 308% in the past six months according to InvestingPro data, announced Monday it has advanced its artificial intelligence-designed GLP-1 therapeutics program by identifying a previously unknown connection between GLP-1 biology and a second pathway related to aging and systemic resilience.

The company’s LensAI platform discovered this complementary regulatory pathway, which MindWalk claims could be targeted alongside GLP-1 receptor agonists (GLP-1RAs) through a proprietary companion therapeutic. According to the company, this dual-pathway approach is first-in-class, with no similar regimens currently approved or marketed. With the company’s earnings report due in 2 days, InvestingPro subscribers can access 9 additional exclusive tips and comprehensive analysis about HYFT’s financial health and market position.

This development builds on MindWalk’s earlier work designing GLP-1 receptor agonists using its HYFT technology platform. The company reported earlier this year that its AI-designed GLP-1 peptides performed comparably to or better than semaglutide in receptor activation assays.

"By applying HYFT and LensAI, we are not simply iterating on existing drugs—we are uncovering first principles that enable the design of safe, durable GLP-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway," said Dr. Jennifer Bath, CEO of MindWalk, in a press release statement.

The company is keeping specific details about the complementary pathway confidential while it pursues validation and intellectual property protection. MindWalk indicated it has initiated IP protection around both the companion therapeutic and the regimen design.

The announcement positions MindWalk to target the longevity therapeutics market, which the company states is projected to exceed $60 billion by 2030. While the company maintains a healthy current ratio of 2.17 and has achieved 18.33% revenue growth over the last twelve months, InvestingPro analysis indicates the stock typically trades with high volatility, making it crucial for investors to conduct thorough due diligence.

MindWalk’s current program includes developing AI-optimized long-acting GLP-1 analogs, advancing a companion therapeutic for the undisclosed complementary pathway, and designing optimal dosing regimens. The company plans to provide updates on lead selection and preclinical parameters in coming quarters.

The Bio-Native AI company is applying its HYFT-driven framework across additional therapeutic areas including oncology, immunology, and vaccine design.

In other recent news, ImmunoPrecise Antibodies Ltd., now rebranded as MindWalk, reported its highest quarterly revenue to date in Q4 2025, reaching $7 million. The company’s gross margin increased significantly to 64% from 48% the previous year, marking a notable improvement in financial performance. Additionally, ImmunoPrecise has advanced its dengue vaccine program to the manufacturing phase, moving from artificial intelligence discovery to pre-clinical testing. This development involves manufacturing the validated dengue epitope for immunization studies using a rabbit model at its Canadian facility. In another strategic move, the company sold its Netherlands-based subsidiary to AVS Bio for $12 million, generating $11.7 million in net proceeds. This transaction aligns with ImmunoPrecise’s ongoing transformation, as it unifies its subsidiaries under the new corporate identity of MindWalk. These recent developments reflect the company’s strategic advancements and operational efficiencies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.